Patents Assigned to Université de Montréal
  • Publication number: 20180265464
    Abstract: Small molecules comprised of azacyclic constrained sphingolipid-like compounds and methods of their synthesis are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, neoplasms, cancers, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Application
    Filed: September 26, 2016
    Publication date: September 20, 2018
    Applicants: The Regents of the University of California, The Université de Montréal
    Inventors: Aimee Edinger, Stephen Hanessian
  • Patent number: 10077236
    Abstract: Small molecules comprised of azacyclic constrained analogs of FTY720 are provided. Formulations and medicaments are also provided that are directed to the treatment of disease, such as, for example, leukemia, and other diseases. Therapeutics are also provided containing a therapeutically effective dose of one or more small molecule compounds, present either as pharmaceutically effective salt or in pure form, including, but not limited to, formulations for oral, intravenous, or intramuscular administration.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: September 18, 2018
    Assignees: The Regents of the University of California, The Université de Montréal
    Inventors: Aimee Edinger, Stephen Hanessian
  • Patent number: 10047103
    Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: August 14, 2018
    Assignees: Bristol-Myers Squibb Company, Universite de Montreal
    Inventors: Jacques Banville, Roger Remillard, Edward H. Ruediger, Daniel H. Deon, Marc Gagnon, Laurence Dube, Julia Guy, Eldon Scott Priestley, Shoshana L. Posy, Brad D. Maxwell, Pancras C. Wong, R. Michael Lawrence, Michael M. Miller
  • Publication number: 20180201953
    Abstract: Methods and compositions for enhancing viral gene transfer, such as lentiviral gene transfer, and improving the efficacy of gene delivery to cells such as primitive hematopoietic cells, are described. These methods and compositions are based on the use of pyrimido[4,5-b]indole derivatives. Cell-based compositions and methods useful for therapeutic indications amenable to treatment with gene therapies, including hematopoietic stem cell therapies, are also described.
    Type: Application
    Filed: September 17, 2015
    Publication date: July 19, 2018
    Applicants: UNIVERSITÉ DE MONTRÉAL, BC CANCER AGENCY, FRED HUTCHINSON CANCER RESEARCH CENTER
    Inventors: Guy SAUVAGEAU, Keith HUMPHRIES, Hans-Peter KIEM, Iman FARES, Jalila CHAGRAOUI
  • Patent number: 9937165
    Abstract: The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: April 10, 2018
    Assignees: Amicus Therapeutics, Inc., Universite de Montreal
    Inventors: Jian-Qiang Fan, Kenneth Valenzano, Gary Lee, Michel Bouvier, Patricia René
  • Patent number: 9872635
    Abstract: Method for measuring the visually-induced postural instability of a person is described, the method comprising a display providing step (S1) during which a visual display device is provided. The display device is arranged so as to display a dynamic visual pattern in at least 50% of the lower half of the visual field of the person, leaving an upper half of the visual field of the person free. The method also comprises a display step (S2) during which a dynamic visual pattern is displayed on the visual display device. The method further comprises a measuring step (S3) during which a parameter representative of the postural instability is measured when the person is gazing at a fix target straight in front while having the dynamic visual pattern displayed on the visual display device.
    Type: Grant
    Filed: September 11, 2013
    Date of Patent: January 23, 2018
    Assignees: Essilor Canada Ltee, Université de Montréal
    Inventors: Jocelyn Faubert, Guillaume Giraudet, Rafael Doti, Eduardo Lugo
  • Patent number: 9871245
    Abstract: There is provided a process for preparing a crystalline electrode material, the process comprising: providing a liquid bath comprising the electrode material in a melted state; and introducing a precursor of the electrode material into the liquid bath, wherein the electrode material comprises lithium, a metal and phosphate. There is also provided a crystalline electrode material, comprising lithium substituted by less than 0.1 atomic of Na or K; Fe and/or Mn, substituted by less than 0.1 atomic ratio of: (a) Mg, Ca, Al and B, (b) Nb, Zr, Mo, V and Cr, (c) Fe(III), or (d) any combinations thereof; and PO4, substituted by less than 20% atomic weight of an oxyanion selected from SO4, SiO4, BO4, P2O7, and any combinations thereof, the material being in the form of particles having a non-carbon and non-olivine phase on at least a portion of the surface thereof.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: January 16, 2018
    Assignees: Johnson Matthey Public Limited Company, Universite de Montreal, La Corporation de L'Ecole Polytechnique de Montreal
    Inventors: Michel Gauthier, Dean MacNeil, Joseph Wontcheu, Patrice Chartrand, Guoxian Liang
  • Patent number: 9862730
    Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: January 9, 2018
    Assignees: Bristol-Myers Squibb Company, Universite De Montreal
    Inventors: R. Michael Lawrence, Michael M. Miller, Dietmar Alfred Seiffert, Shoshana L. Posy, Pancras C. Wong, Jacques Banville, Edward H. Ruediger, Daniel H. Deon, Alain Martel, François Tremblay, Julia Guy, Jean-François Lavallée, Marc Gagnon
  • Publication number: 20170334904
    Abstract: Pyrimido[4,5-b]indole derivatives are provided. These compounds are useful to expand hematopoietic stem cell populations, particularly, human hematopoietic stem cell populations. The compounds are also useful in the medical treatment of diseases that involve hematopoietic stem cells.
    Type: Application
    Filed: December 2, 2016
    Publication date: November 23, 2017
    Applicant: UNIVERSITÉ DE MONTRÉAL
    Inventors: Guy SAUVAGEAU, Yves GAREAU, Rejean RUEL, Stephane GINGRAS, Iman FARES
  • Patent number: 9757378
    Abstract: Novel methods for modulating acute myeloid leukemia stem/progenitor cell expansion and/or differentiation are disclosed. These methods are based on the use of aryl hydrocarbon receptor (AhR) modulators and/or compounds of formula I or II Screening assays to identify compounds that may be useful for inhibiting and/or eliminating AML initiating cells using AhR modulators and/or the compounds of formula I or II are also disclosed. The use of pharmaceutically acceptable agonists of the AhR for preventing or inhibiting minimal residual disease (MRD) in an AML patient is also disclosed.
    Type: Grant
    Filed: April 4, 2014
    Date of Patent: September 12, 2017
    Assignees: UNIVERSITE DE MONTREAL, RSEM, LIMITED PARTNERSHIP
    Inventors: Guy Sauvageau, Josee Hebert, Caroline Pabst
  • Patent number: 9722240
    Abstract: The present invention is concerned with novel compounds derived from polyquinonic ionic compounds and their use in electrochemical generators.
    Type: Grant
    Filed: June 2, 2010
    Date of Patent: August 1, 2017
    Assignees: ACEP INC., SCIENTIFIQUE (CNRS), CENTRE NATIONAL DE LA RECHERCHE, UNIVERSITE DE MONTREAL
    Inventors: Michel Armand, Christophe Michot, Nathalie Ravet
  • Publication number: 20170210624
    Abstract: There is provided a process for producing LiMXO4, comprising the steps of reacting a source of lithium, a source of M, and a source of X together, in a melted state at a reaction temperature between 900 to 1450 C, in the presence of an excess of (A) a solid-solid reducing couple having an oxygen partial process at equilibrium (pO2) comprised between 10?8 and 10?15 atm at said reaction temperature according to an Ellingham-Richardson diagram for oxides, or (B) one component of the solid-solid reducing couple together with a gas-gas reducing couple having an oxygen partial pressure equilibrium (pO2) between 10?8 and 10?15 atm at said reaction temperature according to an Ellingham-Richardson diagram of oxides, and under thermic equilibrium and thermodynamic equilibrium. There is also provided a LiMXO4 melt-solidified product free from off-composition impurities.
    Type: Application
    Filed: May 26, 2015
    Publication date: July 27, 2017
    Applicants: JOHNSON MATTHEY PUBLIC LIMITED COMPANY, UNIVERSITÉ DE MONTRÉAL, LA CORPORATION DE LÉECOLE POLYTECHNIQUE DE MONTRÉAL
    Inventors: Michel GAUTHIER, Patrice CHARTRAND, Majid TALEBI-ESFANDARANI, Pierre SAURIOL, Mickael DOLLÉ, Jasmin DUFOUR, Guoxian LIANG
  • Patent number: 9670506
    Abstract: The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: June 6, 2017
    Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, ACADEMISCH ZIKENHUIS LEIDEN, CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS, UNIVERSITE DE MONTREAL, ARIZONA BOARD OF REGENTS, SANOFI PASTEUR LIMITED
    Inventors: Giuseppe Pantaleo, Thierry Calandra, Alexandre Harari, Thierry Roger, Mariano Esteban, Bertram Jacobs, Karen Kibler, Cornelius Melief, Rafick-Pierre Sekaly, Elias Haddad, James Tartaglia
  • Patent number: 9598419
    Abstract: The present invention provides thiazole compounds of Formula I wherein X, Y, Z, X1, X2, X3, X4, X5, R1, R2, R4, R5, R6, R7, and W, are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug, ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: March 21, 2017
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Alain Martel, Francois Tremblay
  • Patent number: 9545416
    Abstract: The present invention relates to pharmaceutical compositions and combination therapies for treating patients having a neoplasm or a proliferative disorder, the combination comprises an inhibitor of the e1F4E gene product, such as ribavirin, and a chemotherapeutic agent, such as cytarabine, wherein said combination therapy overcomes resistance developed in patients during anti-neoplastic treatment. The present invention also provides for the use of a combination therapy for treating patients having a neoplasm, a proliferative disorder, pre-neoplasm or a precancerous lesion, comprising an inhibitor of the e1F4E gene product, a chemotherapeutic agent, and a therapeutically effective amount of a hedgehog pathway inhibitor, such as GDC-0449; and the method of using said combination therapy.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: January 17, 2017
    Assignee: Universite de Montreal
    Inventors: Katherine Borden, Hiba Zahreddine, Biljana Culjkovic Kraljacic
  • Patent number: 9523698
    Abstract: A method for diagnosing the presence of hereditary spastic paraplegia (HSP) or predicting the risk of developing HSP in a human subject, comprising detecting the presence or absence of a defect in a gene encoding a polypeptide comprising the sequence of FIG. 9 (SEQ ID NO: 19), in a nucleic acid sample of the subject, whereby the detection of the defect is indicative that the subject has or is at risk of developing HSP.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: December 20, 2016
    Assignees: Val-Chum L.P., The Royal Institution for the Advancement of Learning/McGill University, Universite de Montreal
    Inventors: Guy A. Rouleau, Paul Valdmanis, Inge Meijer, Pierre Drapeau, Patrick Dion
  • Patent number: 9518064
    Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: December 13, 2016
    Assignees: Bristol-Myers Squibb Company, Universite De Montreal
    Inventors: Alain Martel, François Tremblay, Anne Marinier, Eldon Scott Priestley, Shoshana L. Posy, R. Michael Lawrence, Michael M. Miller
  • Publication number: 20160345553
    Abstract: There are provided herein transgenic non-human animals and cells comprising a transgene encoding either a mutated human melanocortin type-4 receptor (hMC4R) protein, wherein the mutated protein is misfolded and retained intracellularly, or a wild-type human melanocortin type-4 receptor (hMC4R) protein. Transgenes and targeting constructs used to produce such transgenic animals and cells are also provided, as well as methods for using the transgenic animals in pharmaceutical screening and as commercial research animals for modeling obesity.
    Type: Application
    Filed: August 12, 2016
    Publication date: December 1, 2016
    Applicant: UNIVERSITE DE MONTREAL
    Inventors: Michel BOUVIER, Patricia RENE, Benjamin TURGEON
  • Patent number: 9500651
    Abstract: A novel method for human minor histocompatibility antigen (MiHA) discovery, novel MiHAs identified using this method, as well as uses of the novel MiHAs, are described. One of the features of the novel method is the inclusion of personalized translated transcriptome and/or exome in the database used for peptide identification by mass spectroscopy (MS). Candidate MiHAs are identified by comparing the personalized transcriptome and/or exome to a reference genome and/or to the transcriptome and/or exome of an HLA-matched subject.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: November 22, 2016
    Assignee: UNIVERSITÉ DE MONTRÉAL
    Inventors: Claude Perreault, Pierre Thibault, Sébastien Lemieux, Diana Paola Granados, Sriranganadane Dev, Mohamed Tariq Daouda, Olivier Caron-Lizotte
  • Patent number: 9493456
    Abstract: Disclosed herein is a compound of Formula I: wherein X, R1, R2, and R3 are as defined herein, or a pharmaceutically acceptable salt thereof to allow the drug to penetrate the cell membrane; or a prodrug, or the compound is labeled with a detectable label or an affinity tag thereof. Also disclosed is a pharmaceutical composition, a method of treating a disorder mediated by melanocortin-4 receptors, and a method of treating obesity using the compounds described.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: November 15, 2016
    Assignee: UNIVERSITE DE MONTREAL
    Inventors: Michel Bouvier, Anne Marinier, Réjean Ruel, Patricia René, Yves Chantigny, Philippe Dagneau, Stéphane Gingras